12:00 AM
Feb 25, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ConfirmMDx for Prostate Cancer diagnostic data

Data from a health economic analysis showed that inclusion of MDxHealth's ConfirmMDx for Prostate Cancer test in the screening and diagnosis of prostate cancer in patients with elevated prostate-specific antigen (PSA) levels who had negative biopsy results would result in an annual cost savings of $588 per patient...

Read the full 227 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >